Roivant Sciences (NASDAQ:ROIV) Shares Gap Up on Strong Earnings

Roivant Sciences Ltd. (NASDAQ:ROIV) gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $28.21, but opened at $29.60. Roivant Sciences shares last traded at $31.7910, with a volume of 2,079,051 shares changing hands.

The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. During the same quarter in the previous year, the firm earned ($0.29) earnings per share.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant reported Q4 earnings that beat expectations, with EPS of -$0.28 versus the consensus estimate of about -$0.29, helping support investor confidence despite still being unprofitable. Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Management highlighted a swing to profitability in the quarter, which traders viewed as a major milestone for the stock and a sign the business is improving operationally. Roivant (ROIV) Climbs 15% on Swing to Profits
• Positive Sentiment: The company said it expects a $950 million Moderna-related payment in July and outlined several upcoming clinical readouts in the second half of 2026, which could be meaningful catalysts for the pipeline. Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts
• Neutral Sentiment: Investor attention is also centered on Roivant’s presentation and earnings-call details, which emphasized the company’s pipeline and strategic settlements rather than a major near-term revenue surprise. Roivant Sciences Ltd. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: The quarter still showed weak fundamentals, including revenue below expectations and a reported loss in the latest filing, so some of the move appears driven by optimism around future catalysts rather than current profitability. Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Wall Street Analysts Forecast Growth

ROIV has been the subject of a number of analyst reports. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective for the company. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research note on Thursday. Weiss Ratings restated a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $34.00 price objective on shares of Roivant Sciences in a research note on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $33.05.

Insider Buying and Selling

In other news, CEO Eric Venker sold 200,000 shares of the firm’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $29.59, for a total value of $5,918,000.00. Following the transaction, the chief executive officer directly owned 1,647,546 shares in the company, valued at approximately $48,750,886.14. This trade represents a 10.83% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa B. Epperly sold 41,861 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $28.68, for a total transaction of $1,200,573.48. Following the completion of the transaction, the director owned 15,804 shares in the company, valued at approximately $453,258.72. The trade was a 72.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 1,332,563 shares of company stock worth $37,759,555. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Roivant Sciences

A number of large investors have recently modified their holdings of ROIV. TD Asset Management Inc increased its stake in Roivant Sciences by 94.7% during the 3rd quarter. TD Asset Management Inc now owns 316,200 shares of the company’s stock valued at $4,784,000 after buying an additional 153,800 shares during the period. Neo Ivy Capital Management increased its stake in Roivant Sciences by 229.6% during the 3rd quarter. Neo Ivy Capital Management now owns 237,392 shares of the company’s stock valued at $3,592,000 after buying an additional 165,362 shares during the period. Fox Run Management L.L.C. acquired a new position in Roivant Sciences during the 3rd quarter valued at about $877,000. Capricorn Fund Managers Ltd boosted its position in shares of Roivant Sciences by 124.4% during the 4th quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock valued at $9,667,000 after purchasing an additional 247,000 shares in the last quarter. Finally, HighVista Strategies LLC boosted its position in shares of Roivant Sciences by 61.4% during the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock valued at $1,496,000 after purchasing an additional 37,590 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Trading Down 4.7%

The company’s 50-day moving average price is $28.46 and its two-hundred day moving average price is $25.02. The company has a market cap of $22.10 billion, a P/E ratio of -51.47 and a beta of 1.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.